clinical topic updates

The Role of Novel Antiandrogens in Prostate Cancer Treatment

by Daniel P. Petrylak, MD

Overview

Targeting of the androgen axis has improved outcomes in patients with prostate cancer. Second-generation androgen receptor (AR) antagonists apalutamide, enzalutamide, and darolutamide extend metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), and clinical trials are underway to compare and evaluate their use in other settings.

Expert Commentary

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and Urology
Codirector, Signal Transduction Research Program
Yale Cancer Center
Yale School of Medicine
New Haven, CT

“With the recent US Food and Drug Administration approval of the second-generation AR antagonists apalutamide, enzalutamide, and darolutamide for nmCRPC, the treatment paradigm has changed for patients with nmCRPC who are at high risk for developing metastasis.”

Daniel P. Petrylak, MD

In clinical trials of patients with nmCRPC, these novel antiandrogens extended metastases-free survival by approximately 2 years, which is a clinically meaningful improvement. Generally, darolutamide has the potential for fewer central nervous system side effects than apalutamide and enzalutamide because of its low penetration of the blood-brain barrier, as shown in preclinical studies. However, head-to-head trials are needed to determine the comparative toxicity profiles. Since this patient population frequently has preexisting comorbidities, I am mindful of the potential for drug-drug interactions and I understand that I may need to adjust the dose or consider an alternative second-generation AR antagonist for some individuals.

Advancements in imaging techniques may also transform the role of these agents in prostate cancer. While clinical trials evaluating the efficacy of novel AR antagonists in nmCRPC used conventional imaging, next-generation imaging provides a higher sensitivity in staging high-risk patients, which may identify patients with occult distant metastatic disease. The clinical implications of these findings are still unknown (ie, even if we change our treatment approach presumptively, based on advanced imaging, we do not yet know the impact that this will have on patient outcomes).

Prostate-specific antigen doubling time (PSADT) is a strong predictor of metastasis in this castration-resistant patient population and it serves to guide treatment. The recommendation for patients with a PSADT of greater than 10 months is observation rather than escalation of therapy. For a PSADT of 10 months or less, secondary hormone therapy (in addition to androgen deprivation therapy) would be an appropriate next step. Those with a PSADT of less than 6 months are at even greater risk.

With the recent US Food and Drug Administration approval of the second-generation AR antagonists apalutamide, enzalutamide, and darolutamide for nmCRPC, the treatment paradigm has changed for patients with nmCRPC who are at high risk for developing metastasis. Not long ago, there were no treatments for this stage. Enzalutamide is a second-generation AR antagonist that is specifically approved for metastatic CRPC. Clinical trials with apalutamide (TITAN trial) and darolutamide (ARASENS trial) are evaluating the use of these agents in the metastatic setting as well. There is also interest in investigating the use of novel antiandrogens in very high-risk patients earlier in the treatment paradigm.

References

Chi KN, Agarwal N, Bjartell A, et al; TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24. doi:10.1056/NEJMoa1903307

Fizazi K, Shore N, Tammela TL, et al; ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235-1246. doi:10.1056/NEJMoa1815671

Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465-2474. doi:10.1056/NEJMoa1800536

Liu Z, Zhang T, Ma Z, et al. Systemic management for nonmetastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Am J Clin Oncol. 2020;43(4):288-297. doi:10.1097/COC.0000000000000660

Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019;75(2):285‐293. doi:10.1016/j.eururo.2018.07.035

Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9:801. doi:10.3389/fonc.2019.00801

Smith MR, Saad F, Chowdhury S, et al; SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546

Smith MR, Saad F, Hussain M, et al. ARESENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol. 2018;36(6 suppl):TPS383. doi:10.1200/JCO.2018.36.6_suppl.TPS383

More in Prostate Cancer

Thumb

Prostate Cancer

Identifying the High-Risk Patient: Prognostic Markers in Advanced Prostate Cancer

expert roundtables by Glen Gejerman, MD, Daniel J. George, MD, William K. Oh, MD, and Neal D. Shore, MD, FACS

Although the incidence of metastatic prostate cancer decreased with the introduction of PSA-based screening, prostate cancer will still be responsi...READ MORE

Thumb

Prostate Cancer

Newer PET/CT Imaging Techniques Promise to Improve Detection of Metastatic Prostate Cancer

patient care perspectives by Peter R. Carroll, MD, MPH, Neal D. Shore, MD, FACS

The question of defining metastatic disease with available imaging techniques is an important one. Globally, current standard imaging techniques in...READ MORE

Thumb

Prostate Cancer

Newer Options for Osseous Metastases in Advanced Prostate Cancer

clinical topic updates by Daniel J. George, MD, Neal D. Shore, MD, FACS

As with other epithelial cancers, metastasis to the bone is a sentinel event in the development of advanced prostate cancer. The bone microenvironm...READ MORE

More In Oncology

MDS & AML

Insights on the Immunobiology of MDS and AML

expert roundtables
by Harry Paul Erba, MD, PhD; Guillermo Garcia-Manero, MD; and David Sallman, MD

MDS & AML

Advances in High-Risk MDS and AML: Novel Targets and Combinations

expert roundtables
by Harry Paul Erba, MD, PhD; Guillermo Garcia-Manero, MD; and David Sallman, MD

MDS & AML

Higher-Risk MDS: Points for Patient Discussion

patient care perspectives
by Guillermo Garcia-Manero, MD